NCT05280470: An ongoing trial by Daiichi Sankyo
This trial is ongoing. It must report results 2 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05280470 |
|---|---|
| Title | A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 9, 2022 |
| Completion date | March 3, 2025 |
| Required reporting date | March 3, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |